A $2.9 million funding injection from the Federal Government will support the rollout of a new saliva-based genetic test for glaucoma in Australia. The Adelaide team behind the technology believe it holds
Read More
The Lancet publishes 24-month data for Apellis SYFOVRE GA therapy
Apellis Pharmaceuticals has responded to “positive” 24-month data for its pioneering geographic atrophy (GA) therapy published in The Lancet, demonstrating “that SYFOVRE is a clinically meaningful treatment” for the disease.
Read More
Read More
IZERVAY Phase 3 clinical study achieves positive 24-month results
Astellas Pharma has announced positive 24-month topline results from the GATHER2 Phase 3 clinical study of IZERVAY, developed by its subsidiary Iveric Bio who recently secured regulatory approval in the US for the therapy.
Read More
Read More
Novartis discontinuing GT005 gene therapy clinical trial for geographic atrophy
Novartis will discontinue development of GT005 gene therapy, a subretinal injection for geographic atrophy (GA), in a blow to the global macular disease community, including Australia where the therapy was being trialled in some hospitals.
Read More
Read More
FDA clears higher dose Eylea; approvals sought in other markets
The US FDA has approved the use of high dose Eylea (aflibercept) for three macular conditions, equating to longer intravitreal injection intervals for patients.
Read More
Read More
Australian-made device by muPharma uses ultrasound to non-invasively deliver eye therapies
Melbourne biotech company muPharma, founded by ophthalmologist Dr Harry Unger and Mr Mark Unger, has developed an investigational device that uses ultrasound to deliver therapies non-invasively through ocular tissues, offering potential advantages over the standard of care for some retinal and corneal diseases.
Read More
Read More
Study to shed light on combined effect of multifocal contact lenses and atropine on myopia
Much effort is going into understanding the impact of combined treatments for myopia management, but little is known about the effect of multifocal contact lenses (MFCLs) with low dose atropine (AT).
Read More
Read More
Iveric Bio reveals vision loss reduction data in investigational geographic atrophy therapy
US biopharmaceutical company Iveric Bio has released new data for its avacincaptad pegol (ACP) therapy for geographic atrophy (GA), which showed up to a 59% risk reduction in rate of vision loss compared to sham treatment at 12 months.
Read More
Read More
How Glaukos iDose TR performed in latest glaucoma trial
Glaukos announced positive results from a trial evaluating the safety of the surgical exchange procedure for its iDose TR (travoprost intraocular implant) for glaucoma.
Read More
Read More
SLT vs eye drops: LiGHT glaucoma trial publishes six-year findings
The landmark LiGHT (Laser in Glaucoma and Ocular Hypertension Trial) study – that ultimately recommended selective laser trabeculoplasty (SLT) as a first-line glaucoma intervention – has published six-year results demonstrating the longer term clinical effectiveness of the laser treatment.
Read More
Read More